ArticleBMC veterinary research2025
Construction of enterovirus G expressing reporter genes for antiviral drug screening assays.
Article in BMC veterinary research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Construction of a reverse genetics and fluorescent reporter system for a bovine enterovirus isolated from cattle with diarrhea.BMC veterinary research · 2026Article
- Monensin and salinomycin exhibit broad-spectrum antiviral activity against enteroviruses by disrupting lysosomal acidification.Archives of virology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
The emergence of Enterovirus G strains harboring recombinant papain-like protease (EV-G-PLP) poses a significant threat to the global swine health with zoonotic potential. Addressing the critical lack of targeted treatments, we developed a reverse genetics system for the CH/20GXNN/PLP2020 strain and generated three isogenic reporter recombinants (GFP/RFP/iLOV) through precise PLP gene substitution. Viral progeny exhibited parental-like replication kinetics, with r20GXNN-iLOV demonstrating genetic stability (> 10 passages) compared to GFP/RFP variants. Plaque phenotyping revealed an inverse correlation between plaque size and insert length at the 2C/3A junction. Leveraging this system, we engineered a high-throughput screening platform identifying four anti-EV-G compounds: niclosamide (0.02 µM), salinomycin (2 µM), chloroquine phosphate (12 µM), and ribavirin (400 µM). This study establishes a reverse genetics platform enabling picornavirus research advancement and reveals structural plasticity in the 2C/3A junction that facilitates antiviral screening. Furthermore, it identifies EV-G-specific drug candidates while providing a framework for pan-picornaviral (including EV-A71) compound discovery.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.